Biovie Inc. entered a material agreement
SEC 8-KRead source ↗
Biovie Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders4 buying, 0 selling4 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds14 adding, 13 cuttingOf 3 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Share count rising (dilution): Diluted shares outstanding rose 390.5% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Biovie Inc.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 390.5% in a year.
- Volatile shares. Over the past year the shares showed annualised volatility of 119% and a beta of 1.9 against the S&P 500.
Latest results
- Earnings per share
- -$0.98 against an average estimate of -$0.79: missed by 24.0%
- Next report
- November 9, 2026
Price chart
- 1 day-4.2%
- 1 week+3.0%
- 1 month-6.2%
- This year+18.1%
- 1 year-21.7%
- 5 years-99.8%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-3.05
Growth
- Share count change
- +390.5%
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Agreement
- Announcement
Biovie Inc. made a public disclosure
SEC 8-KRead source ↗
No model value for Biovie Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Biovie Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.98 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Biovie Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 9, 2026, after the close.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.63 | +79% | — | 0% |
| Next | −$0.57 | +10% | — | 0% |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Sept 2025 | −$0.79 | −$0.98 | −24.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 7.0% of tradable shares
- Days to cover
- 1.87 at average volume
- Short interest, 1 month
- −48% to October 15, 2026
- Held by institutions
- 22% of shares
- Held by insiders
- 0.5% of shares
- Employees
- 13 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| BIVI | −74% | +73% | −84% | −84% | −94% | +18% |
| Industry peers (median) | −35% | −57% | −17% | −28% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| BIVI | 25% | 50% | 42% | 25% | 17% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| BIVI | −90% | −76% | −89% | −94% | −95% | −58% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since September 18, 2020: 100% from February 3, 2021 to August 18, 2026. Getting back needed a 464734% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.96 – $2.28
- From 52-week high
- −39.9%
- vs 50-day average
- −15.9%
- vs 200-day average
- −9.8%
- Volatility (1 year)
- 119%
- Beta vs S&P 500
- 1.89
Fundamentals
Dividends, buybacks and capital spending
- Diluted share count
- +390.5%
- year over year
Who owns it
Funds buying and selling- Reported value
- $2.9M
- Institutions reporting
- 35
- Shares held vs prior quarter
- ▲ 44.1%
- Positions opened / closed
- 6 / 3
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Morgan Stanley | $1.2M | 605K | 40.8% | ▲ 704.9% |
| Diametric Capital, LP | $497,873 | 257K | 17.3% | ▼ 30.6% |
| Renaissance Technologies LLC | $248,161 | 128K | 8.6% | ▲ 88.3% |
| Citadel Advisors LLC | $186,147 | 96K | 6.5% | ▲ 111.9% |
| Vanguard Capital Management LLC | $137,558 | 71K | 4.8% | ▼ 15.7% |
| Geode Capital Management, LLC | $137,257 | 71K | 4.8% | ▼ 16.0% |
| Philadelphia Trust Co | $97,000 | 50K | 3.4% | ▼ 33.3% |
| Vanguard Fiduciary Trust Co | $72,861 | 38K | 2.5% | 0.0% |
| Jane Street Group, LLC | $69,569 | 36K | 2.4% | ▲ 57.3% |
| Prelude Capital Management, LLC | $63,211 | 33K | 2.2% | ▼ 64.6% |
| Cambridge Investment Research Advisors, Inc. | $54,000 | 28K | 1.9% | New |
| Northern Trust Corp | $42,331 | 22K | 1.5% | ▲ 53.8% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biovie Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $49,118 4 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $49,118 net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Kim Joanne Wendy Chief Financial Officer | August 28, 2026 | Buy | 2,500 | $2.18 | $5,450 |
| Chappell Amy Suzon Director | August 28, 2026 | Buy | 727 | $2.16 | $1,570 |
| Palumbo Joseph M Chief Medical Officer | August 28, 2026 | Buy | 4,843 | $2.16 | $10,461 |
| Do Cuong V President & CEO | August 27, 2026 | Buy | 15,210 | $2.08 | $31,637 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
- DEF 14A Proxy statement
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- S-1 FORM S-1 REGISTRATION STATEMENT
- S-3 FORM S-3 REGISTRATION STATEMENT
- 10-Q Quarterly report
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Biovie Inc. in brief
- What does Biovie Inc. do?
- Biovie Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.
- What is Biovie Inc.'s stock ticker?
- Biovie Inc. trades under the ticker BIVI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Biovie Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Morgan Stanley, Diametric Capital, LP and Renaissance Technologies LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Biovie Inc. stock?
- Over the last 12 months, Biovie Inc.'s directors and officers reported 4 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Biovie Inc.'s next earnings date?
- Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biovie Inc. announces its own schedule.
Follow research on Biovie Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.